| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| Other Sizes |
| Targets |
The primary target of D-myo-inositol 1,4,5-trisphosphate is the IP₃ receptor (IP₃R), a ligand-gated calcium channel located on the endoplasmic reticulum membrane. By binding to IP₃R, IP₃ triggers the release of calcium ions from the endoplasmic reticulum into the cytosol. This calcium signaling cascade regulates numerous cellular processes, including muscle contraction, neurotransmission, secretion, and gene expression.
|
|---|---|
| ln Vitro |
One of the products of myo-inositol phosphate is the second messenger, D-inositol 1,4,5-trisphosphate (1,4,5-IP3). When Pr55Gag is complexed with D-myo-inositol 1,4,5-trisphosphate—an inositol lacking a lipid group and containing a divalent phosphate group—its dissociation constant (KD) is 2170 μM. D-inositol 1,4,5-trisphosphate (KD=568 μM) and 1,3,4,5-IP4 (KD=526 μM) have nearly equal binding affinities to matrix (MA) [1].
In vitro, IP₃ is used to study calcium signaling in various cell types. It activates IP₃ receptors on the endoplasmic reticulum, leading to the release of Ca²⁺. The compound is a potent second messenger that can be microinjected into cells or applied to permeabilized cell preparations to study calcium-dependent processes. Its activity can be measured using fluorescent calcium indicators. |
| ln Vivo |
In vivo, IP₃ plays a critical role in calcium signaling and cellular physiology. However, the compound itself is not administered as a therapeutic agent due to its rapid metabolism and inability to cross cell membranes. Its effects are studied through the manipulation of the phospholipase C pathway or through the use of cell-permeable analogs.
|
| Enzyme Assay |
For in vitro receptor binding assays, IP₃ is evaluated for its ability to bind to IP₃ receptors. Radiolabeled IP₃ (e.g., ³H-IP₃) is incubated with membrane preparations containing IP₃ receptors and varying concentrations of unlabeled IP₃. Bound and free ligand are separated by filtration or centrifugation. Non-specific binding is determined in the presence of excess unlabeled IP₃. Binding affinity (Kd) is calculated from saturation or competition binding curves.
|
| Cell Assay |
For in vitro cell-based assays, IP₃ is typically tested on permeabilized cells or isolated endoplasmic reticulum vesicles. Cells are permeabilized with digitonin or streptolysin-O, and IP₃ is added at various concentrations (typically 0.01-100 µM). Calcium release from the endoplasmic reticulum is measured using fluorescent calcium indicators such as Fluo-4 or Fura-2. The EC₅₀ for calcium release is determined from dose-response curves.
|
| Animal Protocol |
For in vivo animal experiments, IP₃ is not typically administered directly due to its inability to cross cell membranes. Instead, researchers use cell-permeable IP₃ analogs or manipulate the phospholipase C pathway to study IP₃-mediated calcium signaling in vivo. Intracellular IP₃ levels can be measured in tissue samples using mass spectrometry or radiometric methods.
|
| ADME/Pharmacokinetics |
Pharmacokinetic data for D-myo-inositol 1,4,5-trisphosphate hexapotassium salt are limited, as it is not used as a therapeutic agent. The compound has a molecular weight of 648.64 g/mol and formula C₆H₉K₆O₁₅P₃. As a highly polar, charged molecule, it is membrane-impermeant and is rapidly metabolized by inositol polyphosphate phosphatases and kinases.
|
| Toxicity/Toxicokinetics |
Toxicological data for IP₃ are limited, as it is an endogenous second messenger rather than a therapeutic agent. At physiological concentrations, it is well-tolerated. At supraphysiological concentrations, it may cause excessive calcium release and cellular toxicity. The compound is classified as a research-grade reagent and is not for human therapeutic use.
|
| References |
[1]. Anraku K, et al. Highly sensitive analysis of the interaction between HIV-1 Gag and phosphoinositide derivatives based on surface plasmon resonance. Biochemistry. 2010 Jun 29;49(25):5109-16.
|
| Additional Infomation |
D-myo-Inositol 1,4,5-trisphosphate hexapotassium salt is a research-use only compound and has not been approved for clinical applications. It is also known as Ins(1,4,5)-P₃ hexapotassium salt and 1,4,5-IP₃ hexapotassium salt. Its molecular weight is 648.64, and its formula is C₆H₉K₆O₁₅P₃. The compound is available from various research chemical suppliers for calcium signaling research.
|
| Molecular Formula |
C6H9O15P3-6.6[K+]
|
|---|---|
| Molecular Weight |
648.63786
|
| Exact Mass |
647.697
|
| CAS # |
103476-24-0
|
| Related CAS # |
D-myo-Inositol-1,4,5-triphosphate trisodium;141611-10-1
|
| PubChem CID |
16219525
|
| Appearance |
White to off-white solid powder
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
15
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
30
|
| Complexity |
539
|
| Defined Atom Stereocenter Count |
6
|
| SMILES |
O[C@H]1[C@@H](OP([O-])([O-])=O)[C@H](O)[C@@H](OP([O-])([O-])=O)[C@H](OP([O-])([O-])=O)[C@H]1O.[K+].[K+].[K+].[K+].[K+].[K+]
|
| InChi Key |
DVOPWCOAGWTTEN-PPKFVSOLSA-H
|
| InChi Code |
InChI=1S/C6H15O15P3.6K/c7-1-2(8)5(20-23(13,14)15)6(21-24(16,17)18)3(9)4(1)19-22(10,11)12;;;;;;/h1-9H,(H2,10,11,12)(H2,13,14,15)(H2,16,17,18);;;;;;/q;6*+1/p-6/t1-,2+,3+,4-,5-,6-;;;;;;/m1....../s1
|
| Chemical Name |
hexapotassium;[(1R,2S,3R,4R,5S,6R)-2,3,5-trihydroxy-4,6-diphosphonatooxycyclohexyl] phosphate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.5417 mL | 7.7084 mL | 15.4169 mL | |
| 5 mM | 0.3083 mL | 1.5417 mL | 3.0834 mL | |
| 10 mM | 0.1542 mL | 0.7708 mL | 1.5417 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
